VHL and nonpapillary renal cell carcinoma: Therefore, even though we believe that compromised VHL function underlies the overall ccRCC responsiveness to ICB therapy, genomic mutations may not be a suitable biomarker for predicting individual ccRCC response to ICB therapy because of the prevalence of compromised VHL functions in ccRCC.